Barr makes new try for FDA approval of Plan B OTC sales

Barr Pharmaceuticals is making a second attempt at getting the FDA to approve its morning-after Plan B contraceptive drug for over-the-counter sales by limiting such sales to women at least 16 years old. The plan submitted to the agency is an attempt to overturn the agency's May ruling against OTC sales of Plan B.

View Full Article in:

Newsday (Long Island, N.Y.) (subscription required)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
BCBS-Louisiana
Baton Rouge, LA
Director, Global Integrity and Compliance, Pharmaceuticals
Alcon
Fort Worth, TX